Un "gran simulador" que requiere alerta temprana | 05 JUL 21

Encefalitis Anti-NMDAR

Su diagnóstico precoz es un desafío apremiante para los psiquiatras.
Autor/a: Matthew Beattie, John Goodfellow, Maria Oto, Rajeev Krishnadas. BJPsych Bulletin (2021)
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas

1 Pollak TA, Lennox BR, Müller S, Benros ME, Prüss H, van Elst LT, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry 2020; 7: 93–108.

2 Al-Diwani A, Pollak TA, Langford AE, Lennox BR. Synaptic and neuronal autoantibody-associated psychiatric syndromes: controversies and hypotheses. Front Psychiatry 2017; 8: 13.

3 Herken J, Prüss H. Red flags: clinical signs for identifying autoimmune encephalitis in psychiatric patients. Front Psychiatry 2017; 8: 25.

4 Endres D, Maier V, Leypoldt F, Wandinger K-P, Lennox B, Pollak TA, et al. Autoantibody-associated psychiatric syndromes: a systematic literatura review resulting in 145 cases. PsycholMed [Epub ahead of print] 7 Sep 2020. Available from: https://doi.org/10.1017/S0033291720002895.

5 Rogers JP, Pollak TA, Blackman G, David AS. Catatonia and the immune system: a review. Lancet Psychiatry 2019; 6(7): 620–30.

6 Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7(12): 1091–8.

7 Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly nonparaneoplastic disorder of both sexes. Brain 2010; 133: 1655–67.

8 Finke C, Kopp UA, Scheel M, Pech L-M, Soemmer C, Schlichting J, et al. Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2013; 74: 284–96.

9 Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10(1): 63–74.

10 Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol 2019; 18(11): 1045–57.

11 Dalmau J, Tüzün E, Wu H-Y, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25–36.

12 Al-Diwani A, Handel A, Townsend L, Pollak T, Isabel Leite M, Harrison PJ, et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry 2019; 6: 235–46.

13 Sarkis RA, Coffey M J, Cooper JJ, Hassan I, Lennox B. Anti-N-methyl- D-aspartate receptor encephalitis: a review of psychiatric phenotypes and management considerations: a report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci 2019; 31: 137–42.

14 Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000; 123(Pt 7): 1481–94.

15 Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12(2): 157–65.

16 Lejuste F, Thomas L, Picard G, Desestret V, Ducray F, Rogemond V, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm 2016; 3(5): e280.

17 Scott JG, Gillis D, Ryan AE, Hargovan H, Gundarpi N, McKeon G, et al. The prevalence and treatment outcomes of antineuronal antibodypositive patients admitted with first episode of psychosis. BJPsych Open 2018; 4(2): 69–74.

18 Lennox BR, Palmer-Cooper EC, Pollak T, Hainsworth J, Marks J, Jacobson L, et al. Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. Lancet Psychiatry 2017; 4(1): 42–8.

19 Bergink V, Armangue T, Titulaer MJ, Markx S, Dalmau J, Kushner SA. Autoimmune encephalitis in postpartum psychosis. Am J Psychiatry 2015; 172(9): 901–8.

20 Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein H-G, Vielhaber S, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013; 70(3): 271–8.

21 SINAPPS Group. Prevalence of Pathogenic Antibodies in Psychosis (PPiP)2 Study. SINAPPS Group, 2019 (http://sinapps.org.uk/ppip2/4593809824).

22 SINAPPS Group. SINAPPS Research Projects: Investigating the Role of Antibodies in Psychosis. SINAPPS Group, 2020 (http://sinapps.org.uk/ home/4594859629).

23 Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016; 50(5): 410–72.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

CONTENIDOS RELACIONADOS
AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023